UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion
In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.
In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”
Amarin closed on Thursday at $5.31.
Latest Ratings for AMRN
|Feb 2015||SunTrust Robinson Humphrey||Upgrades||Neutral||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.